This is a phase 2 trial of foscenvivint in liver cirrhosis patients caused by HIV/HCV co-infection with hemophilia to evaluate the efficacy, safety and pharmacokinetics.

Start Date08 May 2024

Sponsor / Collaborator

Tokyo Metropolitan Komagome Hospital

[+1]

NCT05863234

/ RecruitingPhase 1/2IIT

Multicenter, Open-label, Dose-escalation Phase I/II Study to Evaluate the Tolerability, Safety, Efficacy and Pharmacokinetics of Repeated Continuous Intravenous PPMX-T003 in Patients With Aggressive NK Cell Leukaemia (ANKL) (Physician-initiated Clinical Trial)

This is Phase I/II Dose-Escalation Study to evaluate the tolerability, safety, efficacy and pharmacokinetics of PPMX-T003 in aggressive NK-cell leukemia.

Start Date21 Sep 2023

Sponsor / Collaborator

Hiroshima University

[+8]

NCT04688034

/ CompletedPhase 1IIT

Phase I Clinical Trial of CBP/Beta-catenin Inhibitor OP-724 in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection with Hemophilia. (OP-724-H101)

To evaluate the safety and tolerability of OP-724 in liver cirrhosis patients caused by HIV/HCV co-infection with hemophilia.

Start Date15 Mar 2021

Sponsor / Collaborator

Tokyo Metropolitan Komagome Hospital

[+2]

100 Clinical Results associated with Tokyo Metropolitan Komagome Hospital

0 Patents (Medical) associated with Tokyo Metropolitan Komagome Hospital

3,051

Literatures (Medical) associated with Tokyo Metropolitan Komagome Hospital

01 Jul 2025·Modern Pathology

Nosologic Reappraisal of the Recently Proposed Calcified Chondroid Mesenchymal Neoplasm Concept in a Series of 20 Cases

Article

Author: Ohshima, Shinsuke ; Yamada, Ryouji ; Eguchi, Kohtaro ; Mori, Taisuke ; Umezu, Hajime ; Yoshimoto, Seiichi ; Motoi, Toru ; Kawai, Akira ; Yatabe, Yasushi ; Yoshida, Akihiko ; Nishino, Shogo ; Hirai, Toshihide

"Calcified chondroid mesenchymal neoplasm (CCMN)" is a recently proposed term for tumors with hypercellular chondroid histology and fusion genes. However, its impact on the present classification framework has not been extensively investigated. In this study, we analyzed 20 tumors with histology that would fit with that reported as "CCMN." With the combined use of RNA sequencing and fluorescence in situ hybridization, 15 tumors were found to have gene fusions, including FN1::FGFR2 (n = 4), FN1::TEK (n = 1), FN1::MERTK (n = 1), PDGFRA::USP8 (n = 2), FN1 rearrangements with undetermined non-FGFR2 partners (n = 4), and PDGFRA rearrangements with undetermined partners (n = 3). FN1 or PDGFRA rearrangement signals were restricted to epithelioid/polygonal cells, indicating that these were neoplastic elements mixed with abundant reactive cells. The fusion-positive tumors were found in 7 men and 8 women aged 29 to 82 years (median, 57 years), and most involved the temporomandibular joints or digits. Tumors showed a chondroid matrix with grungy calcification and cellular components with epithelioid/polygonal cells and were divided into 2 groups the histology of which corresponded to chondroid tenosynovial giant cell tumor or soft-tissue chondroma. Three fusion-positive tumors harbored calcium pyrophosphate dihydrate crystals. Nuclear atypia was frequent. Gene fusions were not detected in the remaining 5 tumors with abundant crystal/calcium deposition, and some may represent reactive conditions. All 20 tumors followed an indolent clinical course, and 4 patients with temporomandibular joint tumors were successfully followed up without surgery for 9 to 60 months. Using "CCMN" as an entity would entail mixed repercussions in diagnostic practice, and how and whether it should be used in diagnosis requires deliberate discussion. The concept may bring some benefits, but it may arguably cause more confusion because it would substantially restructure the conventional framework by drawing a boundary within the chondroma and conflating the chondroma with chondroid tenosynovial giant cell tumor.

01 Jun 2025·Current Problems in Cancer

Efficacy of atezolizumab, bevacizumab, carboplatin, and paclitaxel for epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer after tyrosine kinase inhibitor failure

Article

Author: Yamaguchi, Yoh ; Hakozaki, Taiki ; Ohe, Yuichiro ; Tokito, Takaaki ; Goto, Koichi ; Nomura, Shogo ; Nishio, Makoto ; Hosomi, Yukio ; Nosaki, Kaname ; Masuda, Ken ; Ariyasu, Ryo ; Azuma, Koichi ; Shinno, Yuki

BACKGROUNDNon-small cell lung cancer (NSCLC) with driver mutations, notably epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase, shows reduced sensitivity to immune checkpoint inhibitors. A subgroup analysis of the IMpower150 data on patients resistant to EGFR tyrosine kinase inhibitors (EGFR-TKI) before enrollment demonstrated prolonged progression-free survival (PFS) with atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) over bevacizumab, carboplatin, and paclitaxel. However, due to the exploratory nature and small sample size, the efficacy of ABCP post-EGFR-TKI failure is still debated. We evaluated ABCP therapy against other platinum-based regimens without immune checkpoint inhibitors in terms of effectiveness and toxicity.METHODSData from patients with advanced or recurrent NSCLC harboring EGFR-sensitizing mutations treated with platinum-based chemotherapy or ABCP at five Japanese hospitals were retrospectively analyzed. Propensity score matching compared efficacy outcomes, including overall response rate (ORR), PFS, and OS.RESULTSOf 183 EGFR mutation carriers, 33 underwent ABCP therapy, while 150 received platinum-based chemotherapy. Following propensity score matching, 32 and 74 patients were analyzed. In the ABCP group, median PFS and OS were 6.8 and 16.7 months compared to 5.8 and 25.7 months with platinum-based chemotherapy, showing no significant differences in PFS (p = 0.46) and OS (p = 0.85). In liver metastases, ABCP yielded a median PFS of 9.9 versus 6.1 months and an ORR of 62.5 % versus 35.7 % relative to platinum-based chemotherapy, without statistical significance (PFS p = 0.16; ORR p = 0.70).CONCLUSIONCompared with platinum-based chemotherapy, ABCP did not improve effectiveness in patients with EGFR-mutated NSCLC after EGFR-TKI failure.

01 Jun 2025·Radiotherapy and Oncology

Contouring compliance and variability of targets and organs at risk in spine stereotactic body Radiotherapy: A 34-Institution study

Article

Author: Ito, Kei ; Mizowaki, Takashi ; Nakajima, Yujiro ; Ito, Yoshinori ; Nishio, Teiji ; Nakamura, Naoki

BACKGROUND AND PURPOSETo ensure the proper implementation of stereotactic body radiotherapy (SBRT) for spinal metastases in a multicenter clinical trial, this study evaluated the compliance and variability in contouring for spine SBRT.MATERIALS AND METHODSA dummy run was conducted at 34 institutions. Computed tomography (CT) and T1/T2-weighted magnetic resonance imaging (MRI) of a patient with fifth thoracic spinal metastasis involving the vertebral body and right pedicle were provided. The observers performed CT-MRI registration and delineated the gross tumor volume (GTV), clinical target volume (CTV), and spinal cord. A radiation oncologist from the study office performed a central review of 17 checklist items. Agreement was assessed using the Dice similarity coefficient.RESULTSAn average of 3.0 protocol deviations per institution was observed. Deviations related to CTV setting in sectors adjacent to the GTV, the addition of a CTV margin to the paraspinal disease, and accurate delineation of the spinal cord were noted in 11, 13, and 12 institutions, respectively. The mean ± standard deviation Dice similarity coefficients for the GTV, CTV, and spinal cord were 0.84 ± 0.06, 0.85 ± 0.04, and 0.76 ± 0.09, respectively. Although nine institutions had clinically unacceptable errors, all met the criteria on the first resubmission. The mean Dice similarity coefficients for the spinal cord improved from 0.66 to 0.82 after resubmission.CONCLUSIONThis study revealed frequent deviations in CTV setting and spinal cord delineation. This dummy run clarified critical points in contouring for spine SBRT, contributing to the standardization of treatment planning.

100 Deals associated with Tokyo Metropolitan Komagome Hospital

100 Translational Medicine associated with Tokyo Metropolitan Komagome Hospital

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 11 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Foscenvivint ( CTNNB1 )	Liver Cirrhosis More	Phase 2

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis